Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015302
Filing Date
2024-11-12
Accepted
2024-11-12 16:01:40
Documents
74
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kala-20240930x10q.htm   iXBRL 10-Q 2623913
2 EX-31.1 kala-20240930xex31d1.htm EX-31.1 15197
3 EX-31.2 kala-20240930xex31d2.htm EX-31.2 15183
4 EX-32.1 kala-20240930xex32d1.htm EX-32.1 6708
5 EX-32.2 kala-20240930xex32d2.htm EX-32.2 6840
  Complete submission text file 0001558370-24-015302.txt   8899174

Data Files

Seq Description Document Type Size
6 EX-101.SCH kala-20240930.xsd EX-101.SCH 65047
7 EX-101.CAL kala-20240930_cal.xml EX-101.CAL 52472
8 EX-101.DEF kala-20240930_def.xml EX-101.DEF 291362
9 EX-101.LAB kala-20240930_lab.xml EX-101.LAB 536454
10 EX-101.PRE kala-20240930_pre.xml EX-101.PRE 404808
77 EXTRACTED XBRL INSTANCE DOCUMENT kala-20240930x10q_htm.xml XML 1305590
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38150 | Film No.: 241447775
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)